Creative Diagnostics, a leading manufacturer and supplier of antibodies, antigens, and assay kits, has announced the launch of its Hantavirus Research Reagents and Products to support hantavirus research and diagnostic assay development. This comprehensive catalog aims to help academic researchers, biopharmaceutical companies, and industrial organizations accelerate the development of diagnostic assays and therapeutic interventions targeting orthohantaviruses, which are emerging zoonotic pathogens belonging to the Bunyaviridae family.
The US Centers for Disease Control and Prevention (CDC) classifies hantaviruses as Category A pathogens due to the serious threat they pose to human health. Infection can lead to hemorrhagic fever with renal syndrome (HFRS) or hantavirus cardiopulmonary syndrome (HCPS), both of which are highly fatal. These pathogens are transmitted to humans via aerosols containing the excreta of infected rodent hosts.
Hantaviruses possess a tripartite negative-strand RNA genome with three genomic RNA segments (S, M, and L) that encode the nucleocapsid protein (N), a precursor glycoprotein (forming two envelope glycoproteins, Gn and Gc), and the viral RNA-dependent RNA polymerase (RdRp). The N protein is the virus's primary structural component, protecting and encapsulating the genomic RNA strands to form viral ribonucleocapsids. Recent studies suggest that the N protein acts in concert with RdRp to play a crucial role in transcription and replication of the viral genome, and it preferentially promotes translation of viral mRNA within the cell.
Currently, there are no antiviral therapies or vaccines available to treat hantavirus-associated diseases. A deeper understanding of the molecular mechanisms underlying the hantavirus life cycle could help identify targets for antiviral therapy and design potential drugs to treat HFRS and HCPS. Given the alarming case-fatality rate, the development of an effective hantavirus vaccine is imperative. Additionally, early clinical manifestations of hantavirus infection are often similar to common seasonal respiratory or influenza-like illnesses, creating an urgent need for highly sensitive, reliable, and standardized laboratory diagnostic tools to enable early differential diagnosis and accurate target validation.
To address these research challenges, Creative Diagnostics offers a range of hantavirus research reagents and products covering multiple strains, including Hantavirus, Puumala virus (PUUV), Seoul virus (SEOV), and Sin Nombre virus (SNV). The new product line includes: recombinant hantavirus antigens for assay development; high-affinity monoclonal and polyclonal antibodies validated for capture and detection uses across multiple platforms, such as Western blot, flow cytometry, immunohistochemistry, and surface plasmon resonance; and supporting reagents for ELISA and rapid immunoassay research.
For detailed product specifications, volume pricing, or to browse the complete list of available viral solutions, visit the official product portal at Creative Diagnostics Hantavirus Products. This launch underscores the company's commitment to supporting researchers in the fight against emerging infectious diseases, providing critical tools for diagnostic and vaccine development.
